Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11793260 | 0.84 | NOS3 (0.41) | HTTKDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL24338021 | 0.80 | ALDH1A1 (0.38) | HTTKDM4EALDH1A1ALOX15MAPK10 | |
| SCHEMBL24924714 | 0.78 | HTT (0.39) | HTTKDM4EALDH1A1ALOX15NOS3 | |
| SCHEMBL13676644 | 0.77 | MET (0.46) | ALDH1A1POLB | |
| SCHEMBL15445181 | 0.77 | NOS3 (0.47) | HTTKDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL22872004 | 0.77 | LMNA (0.34) | ALDH1A1ALOX15HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28864710 | 0.76 | MET (0.46) | ALDH1A1POLB | |
| SCHEMBL19489957 | 0.75 | DPP4 (0.39) | — | |
| SCHEMBL8709873 | 0.75 | ALDH1A1 (0.47) | HTTKDM4EALDH1A1ALOX15MAPK10 | |
| SCHEMBL24446591 | 0.74 | NOS3 (0.35) | KDM4EALDH1A1HSD17B10NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HTT 3293/4885KDM4E 2437/4885ALDH1A1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.